Knight Therapeutics GUD.TO · CAD

Its shares trade on Toronto Stock Exchange under the ticker GUD.TO. It has been listed since 28 February 2014. In the fiscal year to 31 December 2024, it reported revenue of C$371.3m and net income of C$4.3m. At that date it held total assets of C$963.8m and shareholders' equity of C$795.1m.

Knight Therapeutics Inc engages in acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. The company is headquartered in Montreal, Quebec. The company went IPO on 2014-02-28. The firm is engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices. The Company’s products are ILUVIEN Fluocinolone acentonid, Nerlynx Neratinib Tablets, Burinex Bumetanide, Probuphine Buprenorphine implant and Movantik Naloxegol.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Jonathan GoodmanExecutive Chairman of the Board, since 2013C$1.5m
• Ms. Samira SakhiaPresident, Chief Executive Officer, Director, since 2016C$3.2m
• Mr. Arvind UtchanahChief Financial OfficerC$2.1m
• Mr. Leopoldo BosanoGlobal Vice President - Manufacturing and OperationsC$612,529
• Mr. Henrique DiasGlobal Vice President - MarketingC$599,301
• Ms. Monica Barbanti PercarioGlobal Vice President - Regulatory and QualityC$571,091
• Ms. Amal KhouriChief Business OfficerC$2.1m
• Mr. James GaleLead Independent DirectorC$156,605
• Mr. Robert LandeIndependent DirectorC$130,707
• Ms. Janice MurrayIndependent DirectorC$128,195
• Mr. Nicolas SujoyIndependent DirectorC$139,412
• Mr. Michael TremblayIndependent DirectorC$118,224

Overall

30

Environment

5

Social

43

Governance

44

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.